A class of potent cancer treatments could shine brighter than previously thought in a broader array of patients, new research suggests. PARP inhibitors, including AstraZeneca’s $AZN pioneering Lynparza, Clovis’ $CLVS Rubraca and GSK’s $GSK Zejula — work by thwarting PARP proteins that help repair damaged DNA in cell — thereby steering cancer cells onto a … Continue reading PARP inhibitors sometimes work beyond BRCA-mutations, researchers may finally know why